Research

Starting Buprenorphine in the Hospital: What a Screening Study Shows

A hospital buprenorphine study reveals a gap between identifying patients and the research team reaching them—and why low trial enrollment should not be mistaken for treatment refusal.

Finding a patient in hospital records is only the first step toward a treatment conversation. In a two-hospital study of starting buprenorphine, a medication used for opioid addiction and pain, more than half of the 434 potentially eligible patients were never approached by the research team. That gap came before those patients could decide whether to be screened for the trial. The study did not establish whether they discussed treatment with their regular hospital clinicians.[1]

A clinician wearing a stethoscope writes on a clipboard.

Buprenorphine is a prescription medication used in opioid addiction treatment and pain care. This trial focused on hospitalized people with chronic pain and opioid misuse or opioid use disorder (OUD). Its screening report, published in October 2026 in Addiction Science & Clinical Practice, follows the steps between an electronic record flag and starting medication through the trial.[1]

For patients and families seeking help with opioid addiction, the distinction matters: a low trial-enrollment number is not a measure of how many people refused treatment. Patients left this research pathway for different reasons, including the research team being unable to reach the care team, already receiving treatment, declining buprenorphine or addiction services, or choosing not to join research.[1] The practical question is who can discuss treatment during the hospital stay, and how that conversation connects to care afterward.

A Record Flag Starts a Review, Not a Diagnosis

The researchers used an automated search of hospital records to build a daily list of possible participants. The search looked for clues such as an opioid-related diagnosis, a medication prescription, an opioid-positive drug test, or documentation about withdrawal. Staff then reviewed the records to determine whether the person appeared to fit the study.[1]

A clue could be misleading. For example, a naloxone prescription could trigger the search even when a later chart review found no apparent evidence of opioid misuse or OUD. Broad wording in clinical notes also brought people onto the list without establishing that buprenorphine treatment was appropriate for them.[1]

That is why the first number in the study is 9,140 records, not 9,140 people who needed to start buprenorphine. During recruitment from October 2022 through October 2024, preliminary review excluded 8,534 records. An addiction specialist excluded another 172, leaving 434 potentially eligible patients. The additional specialist exclusions appear in the study’s flowchart and explain how the starting total narrows to 434.[1]

The review also served a different purpose from deciding who could ever receive addiction care. Some people were too medically unstable to participate in the study’s assessment or discussion at that moment. Being excluded from that process did not necessarily mean they were clinically ineligible for treatment.[1]

Where the Hospital Study’s Recruitment Path Narrowed

For this trial, researchers first sought the attending physician’s permission to approach a patient. A research assistant trained to describe buprenorphine then explained the treatment and offered screening. Interested patients underwent further assessment for the trial and treatment.[1]

The table follows the 434 patients who remained after the initial record reviews. Each row shows what happened before the next stage, rather than treating everyone who left the pathway as having made the same decision.[1]

From potentially eligible to starting buprenorphine through the trial[1]
Research stage Number What happened before the next stage
Potentially eligible after record reviews 434 233 were not approached by the research team
Approached by the research team 201 158 did not proceed to screening
Assessed for the study 43 14 were found ineligible
Eligible for the study 29 6 declined study participation
Enrolled and started buprenorphine 23 This is the trial’s initiation count

Among the 233 not approached, the research team could not contact the care team for 64, and 36 were discharged before assessment. The care team did not approve an approach for 87. For another 46, the care team reported no opioid misuse or chronic pain. These are recorded categories within the recruitment process, not a count of people denied routine treatment.[1]

The 158 who did not proceed to screening also had different circumstances. The flowchart lists 97 as not interested in buprenorphine, 28 as declining addiction services, 20 as not interested in research, and 13 as already receiving OUD treatment. Combining those groups into a single treatment-refusal category would erase distinctions that matter.[1]

The authors reported an initiation rate of about 5%: 23 who enrolled and started buprenorphine out of the 434 potentially eligible patients. That percentage describes this trial pathway. People who did not enter the trial cannot all be counted as refusing routine treatment. More than half of the denominator had not been approached for the study, and the analysis did not count every clinical conversation or treatment start outside it.[1]

What the Numbers Cannot Explain About a Patient’s Decision

The report documents where recruitment narrowed, but it did not systematically assess why patients declined treatment. A category such as “not interested in buprenorphine” records a response without explaining the person’s reasoning. It cannot tell us whether a particular patient had questions about pain, withdrawal, prior treatment or something else.[1]

The authors discuss stigma and patient concerns as possible barriers. They also suggest that more precise electronic screening, potentially using artificial intelligence, could improve identification. These are directions for further work. This report did not test whether a new screening tool or a change in the conversation would increase treatment starts.[1]

A separate study illustrates why questions about the hospital process deserve attention alongside patient decisions. Riley Shearer and colleagues interviewed 57 providers at 12 community hospitals in 2021–2022. Providers described difficulty arranging ongoing outpatient care as discouraging them from starting medication in the hospital. That finding reflects the perspectives of a selected group of hospital staff. It does not explain the decisions of patients or care teams in the buprenorphine screening trial.[2]

For someone seeking care, the practical implication is to make the next step specific: who can discuss treatment during this admission, and who would help continue it afterward? Those are useful questions even when a research screening result cannot supply the answer.

Make Room for a Treatment Conversation

A May 2026 expert-consensus study in JAMA Network Open examined hospital medication-initiation approaches for people with severe OUD who used fentanyl and similar opioids. In their discussion of newer approaches with limited evidence, Shawn M. Cohen and colleagues recommended explaining those evidence limits to patients and making treatment decisions together. Their work surveyed hospital addiction specialists about treatment approaches, with 42 responding in the first round and 41 in the second. It assessed expert agreement, not whether a particular conversation improved patient outcomes.[3]

For a patient, shared decision-making means having room to discuss what matters to them and to understand the clinician’s reasoning. Questions that can help make that conversation concrete include:

  • What treatment options fit my opioid use, pain and current medical condition? Ask the clinician to explain the purpose of the proposed medication and the alternatives.
  • What should I understand about starting buprenorphine in the hospital? Ask what the team would monitor, what remains uncertain, and how your current medicines affect the plan.
  • Is this discussion about my clinical care, joining a research study, or both? Ask the team to explain the difference and what care options are available outside the study.
  • If I start treatment here, who will help me continue after discharge? Ask for the person or service responsible for arranging the next step.

The next step deserves the same attention: connecting with care after hospital discharge means turning a medication plan or referral into an actual connection with outpatient care.

The screening study makes one early step visible: a name on a list still has to become contact with a person. Understanding where that contact did or did not happen helps readers ask better questions about access, while leaving room for the patient’s own goals and an individualized clinical assessment.

Get Treatment Help

If you or someone you love is struggling with addiction, getting help is just a phone call away, or consider trying therapy online with BetterHelp.

Exclusive offer: 20% Off BetterHelp*

Following links to the BetterHelp website may earn us a commission that helps us manage and maintain AddictionHelp.com. *Get 20% off your first month of BetterHelp. Offer valid for new BetterHelp users only. Offer cannot be combined with insurance.

Written by
Chris Carberg is the Founder of Addiction Help

AddictionHelp.com Founder & Mental Health Advocate

Chris Carberg is the Co-Founder of AddictionHelp.com, and a long-time recovering addict from prescription opioids, sedatives, and alcohol.  Over the past 15 years, Chris has worked as a tireless advocate for addicts and their loved ones while becoming a sought-after digital entrepreneur. Chris is a storyteller and aims to share his story with others in the hopes of helping them achieve their own recovery.

View all blog posts
A city bus with a Downtown Seattle destination sign on a wet street.
A pharmacist selecting a medication box from a pharmacy shelf.
Abstract cut-paper illustration of an open ledger beneath a circle of plum, teal and coral forms.

Subscribe to our newsletter

Our free email newsletter offers guidance from top addiction specialists, 
inspiring sobriety stories, and practical recovery tips.

  • Treatment center locator
  • Help you can trust
  • Unbiased support

Newsletter signup for Addiction Help.

This field is for validation purposes and should be left unchanged.